Although hs-cTnI is effective at enabling the early rule out of myocardial infarction in patients with kidney impairment,4,5 use did not improve outcomes in patients with elevated levels whether they had kidney impairment or not. This evidence concerns the gene TNNI3 and myocardial infarction.